Study Objectives: Measurement tools for sleep inertia, a common and important idiopathic hypersomnia symptom, are limited. For individuals with idiopathic hypersomnia, this post hoc analysis proposes a minimal clinically important difference (MCID) for the Sleep Inertia Visual Analog Scale (SI-VAS), which assesses difficulty waking up. Methods: Data from the pivotal phase 3, double-blind, placebo-controlled, randomized withdrawal study (NCT03533114) of low-sodium oxybate in adults with idiopathic hypersomnia were used to estimate an SI-VAS MCID anchored to the Patient Global Impression of Change, Idiopathic Hypersomnia Severity Scale, and Functional Outcomes of Sleep Questionnaire. Results: Of 109 participants included, the majority female (69.7%) and White (81.7%), most were at least moderately ill (95%) per baseline Clinical Global Impression of Severity. SI-VAS score changes were strongly associated with Patient Global Impression of Change levels (Kruskal–Wallis test statistic, 110.2; P < .0001). Estimated mean (standard error) difference in SI-VAS scores between consecutive Patient Global Impression of Change levels was 10.9 (0.8) mm, suggesting an MCID estimate of 10–12 mm. SI-VAS was also highly correlated with Idiopathic Hypersomnia Severity Scale (Pearson r, 0.79; P < .0001) and Functional Outcomes of Sleep Questionnaire (Pearson r, −0.74; P < .0001). Mean (standard error) SI-VAS change per 4-unit Idiopathic Hypersomnia Severity Scale change (MCID) was 6.0 (0.3) mm and per 2-unit Functional Outcomes of Sleep Questionnaire change (cutpoint) was 8.5 (0.5) mm. Conclusions: Establishing an MCID strengthens the SI-VAS value, adds context for findings related to sleep inertia in individuals with idiopathic hypersomnia from the phase 3 study, and aids clinicians in identifying clinically meaningful changes in sleep inertia to improve patient outcomes. Clinical Trial Registration: Registry: ClinicalTrials.gov; Name: A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension; URL: <a href="https://www.clinicaltrials.gov/study/NCT03533114">https://www.clinicaltrials.gov/study/NCT03533114</a>; Identifier: NCT03533114. Citation: Bogan RK, Fuller DS, Whalen M, Casstevens C, Schneider LD. A minimal clinically important difference for the sleep inertia visual analog scale in idiopathic hypersomnia. J Clin Sleep Med. 2025;21(7):1209–1216.

A minimal clinically important difference for the sleep inertia visual analog scale in idiopathic hypersomnia

期刊论文
发表日期：

2025年7月1日

查看全文

Richard K. Bogan,
Douglas S. Fuller,
Marisa Whalen,
Cristina Casstevens,
Logan D. Schneider

摘要

Study Objectives:

Measurement tools for sleep inertia, a common and important idiopathic hypersomnia symptom, are limited. For individuals with idiopathic hypersomnia, this post hoc analysis proposes a minimal clinically important difference (MCID) for the Sleep Inertia Visual Analog Scale (SI-VAS), which assesses difficulty waking up.

Methods:

Data from the pivotal phase 3, double-blind, placebo-controlled, randomized withdrawal study (NCT03533114) of low-sodium oxybate in adults with idiopathic hypersomnia were used to estimate an SI-VAS MCID anchored to the Patient Global Impression of Change, Idiopathic Hypersomnia Severity Scale, and Functional Outcomes of Sleep Questionnaire.

Results:

Of 109 participants included, the majority female (69.7%) and White (81.7%), most were at least moderately ill (95%) per baseline Clinical Global Impression of Severity. SI-VAS score changes were strongly associated with Patient Global Impression of Change levels (Kruskal–Wallis test statistic, 110.2; P < .0001). Estimated mean (standard error) difference in SI-VAS scores between consecutive Patient Global Impression of Change levels was 10.9 (0.8) mm, suggesting an MCID estimate of 10–12 mm. SI-VAS was also highly correlated with Idiopathic Hypersomnia Severity Scale (Pearson r, 0.79; P < .0001) and Functional Outcomes of Sleep Questionnaire (Pearson r, −0.74; P < .0001). Mean (standard error) SI-VAS change per 4-unit Idiopathic Hypersomnia Severity Scale change (MCID) was 6.0 (0.3) mm and per 2-unit Functional Outcomes of Sleep Questionnaire change (cutpoint) was 8.5 (0.5) mm.

Conclusions:

Establishing an MCID strengthens the SI-VAS value, adds context for findings related to sleep inertia in individuals with idiopathic hypersomnia from the phase 3 study, and aids clinicians in identifying clinically meaningful changes in sleep inertia to improve patient outcomes.

Clinical Trial Registration: Registry: ClinicalTrials.gov; Name: A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension; URL: https://www.clinicaltrials.gov/study/NCT03533114; Identifier: NCT03533114.

Citation:

Bogan RK, Fuller DS, Whalen M, Casstevens C, Schneider LD. A minimal clinically important difference for the sleep inertia visual analog scale in idiopathic hypersomnia. J Clin Sleep Med. 2025;21(7):1209–1216.